Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis

Hedjoudje, Abdellah; Dayyeh, Barham K. Abu; Cheskin, Lawrence J.; Adam, Atif; Neto, Manoel Galvão; Badurdeen, Dilhana; Morales, Javier Graus; Sartoretto, Adrian; Nava, G; Vargas, Eric J.; Sui, Zhixian; Fayad, Lea; Farha, Jad; Khashab, Mouen A.; Kalloo, Anthony N.; Alqahtani, Aayed R.; Thompson, Christopher C.; Kumbhari, Vivek

doi:10.1016/j.cgh.2019.08.022

Cited by 182 publications

(141 citation statements)

References 43 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…This study differs in the reported %TWL outcome between ESG and LSG at 12 months. At the time this study was under review, two other meta-analyses were published describing the pooled rates of ESG [50,51]. Our results are on-par with their reported pooled rates, however, our study is unique owing to the fact that we have put the 12-month pooled outcomes of ESG in perspective to the 12-months' pooled outcomes of LSG, and in addition this study is more up-to-date with 1815 patients.…”

Section: Discussionmentioning

confidence: 50%

Outcomes of endoscopic sleeve gastroplasty; how does it compare to laparoscopic sleeve gastrectomy? A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background and study aims Endoscopic sleeve gastroplasty (ESG) is a novel moderately invasive technique in endo-bariatrics as compared to laparoscopic sleeve gastrectomy (LSG). Data is limited as to its efficacy and safety. Methods We searched multiple databases from inception through August 2019 to identify studies that reported on ESG in the treatment of obesity. Our goals were to calculate the pooled rates of total weight loss (%TWL), excess weight loss (%EWL), and body mass index (BMI) at 1 month, 6 months, and 12 months with ESG. We included studies that reported on LSG, in a similar time frame as ESG, and compared the 12-month outcomes. Results From eight studies on ESG (1815 patients), the pooled rates of %TWL at 1 month, 6 months, and 12 months were 8.7 (7.2–10.2), 15.3 (14.1–16.6) and 17.1 (15.1–19.1), respectively. The pooled rates of %EWL at 1 month, 6 months, and 12 months were 31.7 (29.3–34.1), 59.4 (57–61.8) and 63 (51.3–74.6), respectively. The pooled rates of BMI at 1 m, 6 m, and 12 m were 32.6 (31–34.3), 30.4 (29–31.8) and 30 (27.7–32.3, I2 = 97), respectively. At 12 months, the pooled %TWL, %EWL and BMI with LSG (7 studies, 2179 patients) were 30.5 (27.4–33.5), 69.3 (60.1–78.4) and 29.3 (27.1–31.4) respectively. On comparison analysis, %TWL with LSG was superior to ESG (P = 0.001). %EWL and BMI were comparable. All adverse events, bleeding and gastro-esophageal reflux disease were significantly lower with ESG when compared to LSG. Conclusion ESG demonstrates acceptable weight loss parameters and seems to have a better safety profile when compared to LSG.

show abstract

Section: Discussionmentioning

confidence: 50%

Outcomes of endoscopic sleeve gastroplasty; how does it compare to laparoscopic sleeve gastrectomy? A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of 17 studies demonstrated similar results with %TBWL 11.2 % and percent excess weight loss (%EWL) 25.44 % at 12 months [8]. A recent meta-analysis of 1772 patients that underwent ESG demonstrated %TBWL of 15.1 % at 6 months and 16.5 % at 12 months [9]. In a multicenter RCT of Aspiration therapy, patients achieved %TBWL of 14.2 % at 12 months and 15.3 % at 24 months [10].…”

mentioning

confidence: 86%

Building an endobariatric program: lessons learned

et al. 2020

Self Cite

View full text Add to dashboard Cite

The emphasis on treating obesity has never been more critical, yet the complexity of delivering care has become more intricate due to new procedures, variable insurance coverage, and inconsistent reimbursement. This is our experience building an endobariatric program and treating overweight and obese patients with endobariatric therapies (EBTs) over 3 years. The primary intention of this manuscript was to educate the reader on how to build an endobariatric program, identify barriers, and provide succinct solutions to establish a successful program. The secondary aim was weight loss outcomes of procedures offered at our institution. We compiled a list of lessons learned, based on the difficulties we experienced to make it easy for others embarking on this journey. Herein, we present a business development strategy to overcome impediments, whilst offering high quality service. The high cost and lack of insurance coverage are significant barriers. Marketing can be costly and is often a factor that is ignored particularly early on, when finances are limited. However, it is an integral component of growing the program. The percentage total body weight loss (%TBWL) at 6 and 12 months post ESG was 17.8 ± 6.48 and 20.6 ± 8.3 (P < 0.001), respectively. The %TBWL at 6 months post IGB was 14.9 ± 9.8 for the Orbera IGB and 12.6 ± 7.4 for the Reshape IGB. There was a trend of preference for ESG compared to IGB placement over the 3 years. The key to building a successful endobariatric program is a motivated physician leader, collaborative bariatric surgeons, institutional support, and marketing. Insurance coverage will likely occur in the near future and programs must be prepared to manage the massive influx of patients that will likely request these procedures.

show abstract

“…The first series of four cases was reported in 2013 by Abu Dayyeh et al who pointed out that ESG may be considered the endoscopic counterpart of laparoscopic sleeve gastrectomy (LSG), although different form the latter one it causes stomach restriction without resection of the corpus/fundus 26 . In a systematic review and meta‐analysis of eight studies overall including 1772 patients treated with OverStitch™ at eight international centres, ESG was shown to be reproducible and to produce clinically significant weight loss with a low rate of severe adverse events 27 …”

Section: Endoscopic Sleeve Gastroplastymentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Salomone¹,

Sharaiha

Boškoski

2020

Liver International

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by noninvasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications. K E Y W O R D S bariatric endoscopy, duodenal mucosal resurfacing, endoscopic sleeve gastroplasty, intragastric balloon, NAFLD, obesity How to cite this article: Salomone F, Sharaiha RZ, Boškoski I. Endoscopic bariatric and metabolic therapies for nonalcoholic fatty liver disease: Evidence and perspectives. Liver

show abstract

Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis

Cited by 182 publications

References 43 publications

Outcomes of endoscopic sleeve gastroplasty; how does it compare to laparoscopic sleeve gastrectomy? A systematic review and meta-analysis

Outcomes of endoscopic sleeve gastroplasty; how does it compare to laparoscopic sleeve gastrectomy? A systematic review and meta-analysis

Building an endobariatric program: lessons learned

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Contact Info

Product

Resources

About